chromomycin A2: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 201841 |
| MeSH ID | M000601468 |
| Synonym |
|---|
| 6992-70-7 |
| chromomycin a2 |
| aburamycin a |
| chromomycin a(sub 2) |
| chromomycinone, 6-(2,6-dideoxy-4-o-(2,6-dideoxy-4-o-methyl-d-lyxo-hexopyranosyl)-d-lyxo-hexopyranoside) 2-(o-2,6-dideoxy-3-c-methyl-l-arabino-hexopyranosyl-(1-3)-o-2,6-dideoxy-d-arabino-hexopyranosyl-(1-3)-2,6-dideoxy-d-arabino-hexopyranoside), monoacetat |
| nsc 131187 |
| AKOS030622852 |
| aburamycin a, nsc 131187 |
| aburamycina |
Chromomycin A2 treated cells depicted several cellular fragments resembling autophagosomes and increased expression of proteins LC3-A andLC3-B. Treatment with chromomycins at 30 nM reduced cell proliferation, but had no significant effect upon cell viability.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chromomycin A2 treated cells depicted several cellular fragments resembling autophagosomes and increased expression of proteins LC3-A and LC3-B." | ( Chromomycin A2 induces autophagy in melanoma cells. Costa-Lotufo, LV; Deusdênia Loiola Pessoa, O; Freitas, HP; Guimarães, LA; Jimenez, PC; Martín, J; Reyes, F; Rocha, DD; Sousa, Tda S; Wilke, DV, 2014) | 2.57 |
| "Treatment with chromomycin A2 at 30 nM reduced cell proliferation, but had no significant effect upon cell viability." | ( Chromomycin A2 induces autophagy in melanoma cells. Costa-Lotufo, LV; Deusdênia Loiola Pessoa, O; Freitas, HP; Guimarães, LA; Jimenez, PC; Martín, J; Reyes, F; Rocha, DD; Sousa, Tda S; Wilke, DV, 2014) | 2.18 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||